Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology

Journal of Alzheimer's Disease

Volumn 18, Issue 3, 2009, Pages 509-513

  Glodzik, Lidia ^a   De Santi, Susan ^a   Rich, Kenneth E ^a   Brys, Miroslaw ^a   Pirraglia, Elizabeth ^a   Mistur, Rachel ^a   Switalski, Remigiusz ^b   Mosconi, Lisa ^a   Sadowski, Martin ^a   Zetterberg, Henrik ^c   Blennow, Kaj ^c   De Leon, Mony J ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b East Tennessee State University   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Memantine; Phosphorylated tau; Total tau

Indexed keywords

BIOLOGICAL MARKER; MEMANTINE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MEMORY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 75149143435     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1183     Document Type: Article

References (18)

1. Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1, 101-110.
2. Wenk GL, Parsons CG, Danysz W (2006) Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17, 411-424.
3. Chan SF, Sucher SJ (2001) An NMDA receptor signaling complex with protein phosphatase 2A. J Neurosci 20, 7985-7992.
4. Farlow MR, Miller ML, Pejovic V (2008) Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 25, 408-422.
5. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566, 261-269.
6. Song MS, Rauw G, Baker GB, Kar S (2008) Memantine protects rat cortical cultured neurons against b-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 28, 1989-2002.
7. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet Neurol 368, 387-403.
8. Gunnarsson DM, Kilander L, Basun H, Lannfelt L (2007) Reduction of phosphorylated Tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 24, 247-252.
9. Reisberg B, Sclan SG, Franssen EH, de Leon MJ, Kluger A, Torossian CL, Shulman E, Steinberg G, Monteiro I, Mcrae T, Bocksay I, Mackell JA, Ferris SH (1993) Clinical stages of normal aging and Alzheimer's disease: The GDS staging system. Neurosci Res Commun 13 (Suppl. 1), 551-554.
10. Reisberg B, Schneck MK, Ferris SH, Schwartz GE, de Leon MJ (1983) The brief cognitive rating scale (BCRS): Findings in primary degenerative dementia (PDD). Psychopharmacol Bull 19, 47-50.
11. Folstein M (1983) The Mini-Mental State Examination. In: Assessment in Geriatric Psychopharmacology, Crook T, Ferris SH, Bartus R, Eds. New Canaan: Mark Powley Associates, pp. 47-51.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). 4 ed. Washington, D.C.: American Psychiatric Association, 1994.
14. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N (2007) Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 419, 18-22. (Pubitemid 46694097)
15. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B (1999) Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiat 156, 531-537.
16. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. New Engl J Med 348, 1333-1341.
17. Lipton SA, Chen H-SV (2004) Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ 11, 18-20.
18. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich K, Switalski R, Mehta P, Pratico D, Zinkowski R, Blennow K, de Leon MJ (2008) Hypometabolism and altered CSF markers in normal ApoE E4 carriers with subjective memory complaints. Biol Psychiatry 63, 609-618.